This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Shanghai Genechem Co., Ltd.. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Innovations by Yangsheng Jin in Tumor Treatment
Introduction
Yangsheng Jin is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of genetic research, particularly in the area of tumor treatment. With a total of 2 patents, his work focuses on the applications of specific human genes in combating cancer.
Latest Patents
Yangsheng Jin's latest patents include groundbreaking research on the human ZFX gene and the human NLK gene. The first patent discloses the uses of the human ZFX gene and associated drugs. This invention outlines methods for tumor treatment, diagnosis, and drug preparation. It also introduces small interfering RNA (siRNA) and nucleic acids that can specifically inhibit the expression of the human ZFX gene. The lentivirus encoding the siRNA can efficiently infect target cells, inhibit ZFX expression, and promote tumor apoptosis, making it a significant advancement in tumor treatment.
The second patent focuses on the human NLK gene and its associated drugs. This invention details the use of the NLK gene for tumor treatment and diagnosis. It constructs an isolated molecule that attenuates the expression of the NLK gene in tumor cells. The NLK interference lentivirus can effectively infect target cells and inhibit the growth of tumor cells, highlighting its importance in cancer therapy.
Career Highlights
Yangsheng Jin is currently associated with Shanghai Genechem Co., Ltd., where he continues to innovate in the field of genetic research. His work has garnered attention for its potential applications in medical science, particularly in oncology.
Collaborations
Yangsheng Jin collaborates with notable colleagues, including Haixiong Han and Xiangying Zhu. Their combined expertise contributes to the advancement of research in genetic therapies.
Conclusion
Yangsheng Jin's contributions to the field of tumor treatment through his innovative patents demonstrate his commitment to advancing medical science. His research on the ZFX and NLK genes holds promise for future cancer therapies, making him a significant figure in the realm of genetic research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile